$0.58
1.90%
Nasdaq, Nov 20, 03:59 pm EST. Closed.
ISIN
US09077A1060
Symbol
BMEA

Biomea Fusion Inc Stock price

$0.57
-0.16 21.91% 1M
-0.76 56.81% 6M
-0.67 53.68% YTD
-0.43 42.56% 1Y
-9.75 94.43% 3Y
-10.89 94.99% 5Y
-18.03 96.91% 10Y
-18.03 96.91% 20Y
Nasdaq, Closing price Fri, Nov 20 2026
-0.01 2.38%
ISIN
US09077A1060
Symbol
BMEA
Industry

Is Biomea Fusion Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,086 stocks worldwide.

Key metrics

Basic
Market capitalization
$41.8m
Enterprise Value
$6.9m
Net debt
positive
Cash
$34.8m
Shares outstanding
72.5m
Valuation
P/E
negative
P/S | estimate
- | -
EV/Sales | estimate
- | -
EV/FCF | ex SBC
negative | negative
P/B
3.4
Financial Health
Equity Ratio
50.5%
Return on Equity
-209.1%
ROCE
-220.0%
ROIC
-
Debt/Equity
0.0
Share-Based Compensation & Dilution
SBC | % of Revenue
$7.0m | -
SBC as % of FCF
-
SBC Growth 1Y
-53.6%
Share Count Growth 1Y
24.7%
Shareholder Yield
-24.7%
Financials
Revenue | estimate
$0.0 | $0.0
EBITDA
$-57.5m
EBIT
$-58.1m
Net Income
$-32.5m
Free Cash Flow | ex SBC
$-47.2m | $-54.1m
Growth
Revenue | estimate
- | -
EBITDA
49.2%
EBIT
49.6%
Net Income
71.0%
Free Cash Flow
53.0%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow | ex SBC
- | -
More
EPS
$-0.4
FCF per Share
$-0.7
Short interest
25.5%
Employees
41
Rev per Employee
$0.0

Biomea Fusion Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Biomea Fusion Inc forecast:

11x Buy
85%
1x Hold
8%
1x Sell
8%

Analyst Opinions

13 Analysts have issued a Biomea Fusion Inc forecast:

Buy
85%
Hold
8%
Sell
8%

Biomea Fusion Inc Events

Past Events
OCT
13
Special Call - Biomea Fusion, Inc.
about one month ago
MAY
5
Special Call - Biomea Fusion, Inc.
7 months ago
APR
28
Special Call - Biomea Fusion, Inc.
7 months ago
MAR
30
Special Call - Biomea Fusion, Inc.
8 months ago
MAR
30
Special Call - Biomea Fusion, Inc.
8 months ago
JAN
14
44th Annual J.P. Morgan Healthcare Conference
10 months ago
OCT
23
Citi's 2025 SMID Cap Biopharma Call Series
about one year ago

Financial data from Biomea Fusion Inc

Jun '26
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 15 15
38% 38%
-
- Research and Development Expense 41 41
55% 55%
-
-58 -58
49% 49%
-
- Depreciation and Amortization 0.54 0.54
71% 71%
-
EBIT (Operating Income) EBIT -58 -58
50% 50%
-
Net Profit -33 -33
71% 71%
-

In millions USD.

Don't miss a Thing! We will send you all news about Biomea Fusion Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Biomea Fusion Inc Stock News

Neutral
GlobeNewsWire
●
10 days ago
SAN CARLOS, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today reported its financial results for the third quarter ended September 30, 2026, and provided a business update.
Neutral
GlobeNewsWire
●
11 days ago
SAN CARLOS, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company focused on diabetes and obesity, today announced that it will present Phase 1 clinical results for BMF-650, its investigational next-generation oral small molecule GLP-1 receptor agonist, at ObesityWeek® 2026.
Neutral
GlobeNewsWire
●
about one month ago
SAN CARLOS, Calif., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company, today announced Phase 1 GLP-131 clinical trial results for BMF-650, its investigational oral small-molecule glucagon-like peptide-1 receptor agonist (“GLP-1 RA”), which demonstrated consistent weight reduction across five multiple asce...
More Biomea Fusion Inc News

Company Profile

Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of irreversible small molecules to treat patients with genetically defined cancers. The company was founded by Thomas Butler and Ramses Erdtmann in August 2017 and is headquartered in Redwood City, CA.

Head office United States
CEO Dr. Hitchcock
Employees 41
Founded 2017
Website www.biomeafusion.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today